WALD - Dr. Suzan Obagi Appointed as Chief Medical Director at Obagi Cosmeceuticals a Subsidiary of Waldencast plc. | Benzinga
LONG BEACH, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Obagi Cosmeceuticals LLC ("Obagi"), a leader in skincare innovation and the originator of medical-grade skincare, is thrilled to announce the appointment of Dr. Suzan Obagi as the Company's first-ever Chief Medical Director. Obagi is a subsidiary of Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform and publicly listed company. Dr. Obagi brings a wealth of experience and expertise to her role, further solidifying Obagi's commitment to providing advanced, transformative skincare solutions.
Dr. Suzan Obagi is a world-renowned, leading board-certified dermatologist and cosmetic surgeon, recognized for her groundbreaking contributions to the fields of dermatology, cosmetic surgery, and skincare. Throughout her illustrious career, Dr. Obagi has become a top authority in aesthetic dermatology, medical-grade skincare, anti-aging treatments, and skin health, focusing her practice across a wide range of skin types, including darker skin. In addition to her practice, Dr. Obagi has trained physicians from around the world on the latest advancements in cosmetic and laser surgery; authored articles and book chapters on skin health restoration, autologous fat augmentation, Botox and soft tissue fillers, chemical peeling, dermabrasion, and lasers; and lectured to medical specialists and surgeons across a variety of specialties including ophthalmologic, facial plastic, cosmetic, oral and maxillofacial and dermatological on many of these topics.
In her role of Chief Medical Director, Dr. Obagi will play a pivotal role in shaping Obagi's product development, portfolio refinement, research initiatives, and educational programs to ensure Obagi continues to provide the gold standard for skincare to the physician-dispensed market. Her extensive knowledge of dermatology and aesthetic medicine, as well as her commitment to evidence-based practices, will ...